Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0019204 (
hepatocellular carcinoma
)
71,386
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Hepatocellular carcinoma
(
HCC
) is the dominant histologic type of primary liver cancer, and hepatitis B virus (HBV) infection is one of the major causes of
HCC
in the chronic HBV. Our study was investigated the association between the polymorphisms of
ACYP2
and
MPHOSPH6
genes and the risk of
HCC
induced by HBV infection. A total of 490 subjects were divided into two groups: 248 HBV patients with
HCC
(Case group), and 242 HBV patients without
HCC
(Control group). Unconditional logistic regression analysis was used to evaluate the association. The genetic association analysis revealed variant of rs12621038 in
ACYP2
gene had a significant association with increasing the risk of HBV-induced
HCC
based on the genotype, dominant and additive model (
P
<0.05). Moreover, our results also showed that minor allele "C" of rs3751862 was prevalent in cases than controls (
P
<0.05), and rs3751862 significantly increased the risk of
HCC
in chronic HBV carriers under genotype and dominant model (
P
<0.05). In addition, the haplotype "T-G-G" in
MPHOSPH6
showed a harmful factor for the HBV-induced
HCC
(
P
<0.05). The results suggested that
ACYP2
and
MPHOSPH6
as the plausible candidate genes may predict the risk of
HCC
after chronic HBV infection in Chinese Han population, and further investigations in studies with a larger sample size and other races are needed to validate our findings. These data provide a theoretical foundation for future studies of this correlation between the polymorphisms of
ACYP2
and
MPHOSPH6
genes and the
HCC
in chronic HBV carriers.
...
PMID:Association of
ACYP2
and
MPHOSPH6
genetic polymorphisms with the risk of hepatocellular carcinoma in chronic hepatitis B virus carriers. 2915 73
Interleukin-6 (IL-6)-type cytokines play important roles in liver (patho-)biology. For instance, they regulate the acute phase response to inflammatory signals and are involved in hepatocarcinogenesis. Much is known about the regulation of protein-coding genes by cytokines whereas their effects on the miRNome is less well understood. We performed a microarray screen to identify microRNAs (miRNAs) in human hepatocytes which are modulated by IL-6-type cytokines. Using samples of 2 donors, 27 and 68 miRNAs (out of 1,733) were found to be differentially expressed upon stimulation with hyper-IL-6 (HIL-6) for up to 72 h, with an overlap of 15 commonly regulated miRNAs. qPCR validation revealed that miR-146b-5p was also consistently up-regulated in hepatocytes derived from 2 other donors. Interestingly, miR-146b-5p (but not miR-146a-5p) was induced by IL-6-type cytokines (HIL-6 and OSM) in non-transformed liver-derived PH5CH8 and THLE2 cells and in Huh-7
hepatoma
cells, but not in HepG2 or Hep3B
hepatoma
cells. We did not find evidence for a differential regulation of miR-146b-5p expression by promoter methylation, also when analyzing the TCGA data set on liver cancer samples. Inducible overexpression of miR-146b-5p in PH5CH8 cells followed by RNA-Seq analysis revealed effects on multiple mRNAs, including those encoding IRAK1 and TRAF6 crucial for Toll-like receptor signaling. Indeed, LPS-mediated signaling was attenuated upon overexpression of miR-146b-5p, suggesting a regulatory loop to modulate inflammatory signaling in hepatocytes. Further validation experiments suggest DNAJC6, MAGEE1,
MPHOSPH6
, PPP2R1B, SLC10A3, SNRNP27, and TIMM17B to be novel targets for miR-146b-5p (and miR-146a-5p).
...
PMID:Cytokine-mediated modulation of the hepatic miRNome: miR-146b-5p is an IL-6-inducible miRNA with multiple targets. 3014 33
